MYGN logo

MYGN
Myriad Genetics, Inc.

2,128
Mkt Cap
$429.2M
Volume
1.03M
52W High
$8.59
52W Low
$3.76
PE Ratio
-1.16
MYGN Fundamentals
Price
$4.91
Prev Close
$4.59
Open
$4.60
50D MA
$4.78
Beta
1.17
Avg. Volume
2.57M
EPS (Annual)
-$3.95
P/B
1.17
Rev/Employee
$305,370.37
$629.69
Loading...
Loading...
News
all
press releases
Aberdeen Group plc Purchases 246,748 Shares of Myriad Genetics, Inc. $MYGN
Aberdeen Group plc raised its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 38.6% in the fourth quarter, according to the company in its most recent filing with the...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
What's Fueling TEM Diagnostics Segment's Strong 2026 Outlook?
TEM's diagnostics arm surges on oncology demand, MRD adoption and rising pricing, with 2026 growth set to stay strong as sequencing and reimbursement expand.
Zacks·13d ago
News Placeholder
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
Viridian Therapeutics (VRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·13d ago
News Placeholder
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Analysts
Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) has been given an average recommendation of "Hold" by the twelve analysts that are currently covering the firm, MarketBeat.com reports. One...
MarketBeat·18d ago
News Placeholder
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·20d ago
News Placeholder
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·26d ago
News Placeholder
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·27d ago
News Placeholder
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.
Zacks·1mo ago
News Placeholder
Myriad Genetics (NASDAQ:MYGN) CEO Buys 40,000 Shares
Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) CEO Samraat Raha bought 40,000 shares of the stock in a transaction on Monday, March 9th. The shares were bought at an average price of $5.00 per...
MarketBeat·1mo ago
News Placeholder
Myriad Genetics (NASDAQ:MYGN) CEO Purchases $200,000.00 in Stock
Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) CEO Samraat Raha bought 40,000 shares of Myriad Genetics stock in a transaction on Monday, March 9th. The shares were purchased at an average...
MarketBeat·1mo ago
<
1
2
...
>

Latest MYGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.